As Ozempic, Mounjaro Grab Share, Can Metformin Get A Leg-Up From Long COVID?
US Prescription Data Show Big Gains For New Generation Drugs
Diabetes and obesity products like Ozempic/Wegovy and Mounjaro are gaining share at the expense of metformin and SGLT-2 inhibitors. Scrip looks at data on prescription shifts in the US while examining if metformin remains attractive and whether a recent study showing efficacy in long COVID treatment could help
